BioSpace News Archive

ATAI Life Sciences AG, a global biotechnology company builder that envisions an end to mental illnesses, has acquired a majority stake in New York-based pharmaceutical company Kures, which targets the important intersection between pain and opioid use disorder

Walt & Company, an award-winning Silicon Valley tech public relations and social media agency, today announced that it has been selected by Neocortix, developers of disruptive Cloud at the Edge virtual data center solutions, to manage the launch of the first-of-its-kind, large-scale mobile research initiative to conduct computational biology

Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers, today provided an update on its progress in advancing the development of its programs.

Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.

Glioblastomas are the most common malignant brain tumors in adults. Treatment options are extremely limited and usually not effective, leading to death for most patients within 12-18 months of diagnosis.

Transgene and Hypertrust Patient Data Care announced as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product.

Forbion, a leading European life sciences venture capital firm, announces the first close at EUR 185 million of its new Forbion Growth Opportunities Fund, focused on investing in late-stage European life sciences companies.

IRLAB announced that a scientific paper reporting the distinctive pharmacological profile of IRL752, in development for the treatment of impaired balance and falls in Parkinson’s disease, is accepted and published online in the Journal of Pharmacology and Experimental Therapeutics, JPET.

Anteris Technologies Limited, a structural heart company advancing the DurAVR™ valve, a novel aortic valve replacement solution, announced that it will host a key opinion leader symposium on Monday, July 20, 2020 at 11:00AM EDT.

Four months ago, Canada was unprepared for the first wave of the COVID-19 pandemic hitting Canadian soil but managed to flatten the curve.